CATALOGO DEI PRODOTTI DELLA RICERCA

FATTOVICH, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.227
EU - Europa 8.672
AS - Asia 2.844
SA - Sud America 14
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 9
AF - Africa 7
Totale 22.785
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.209
GB - Regno Unito 3.641
CN - Cina 2.208
FR - Francia 1.066
IE - Irlanda 781
DE - Germania 748
SE - Svezia 677
RU - Federazione Russa 517
FI - Finlandia 498
SG - Singapore 489
IT - Italia 477
UA - Ucraina 164
TR - Turchia 67
KR - Corea 19
BE - Belgio 17
CA - Canada 15
IN - India 15
PL - Polonia 14
NL - Olanda 13
EU - Europa 9
ES - Italia 7
JP - Giappone 7
AU - Australia 6
RO - Romania 6
BG - Bulgaria 5
BR - Brasile 5
CL - Cile 5
CZ - Repubblica Ceca 5
PT - Portogallo 5
VN - Vietnam 5
AT - Austria 4
CH - Svizzera 4
EG - Egitto 4
HU - Ungheria 4
IR - Iran 4
MD - Moldavia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
GR - Grecia 3
IL - Israele 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
SA - Arabia Saudita 3
TH - Thailandia 3
AR - Argentina 2
AZ - Azerbaigian 2
EE - Estonia 2
ID - Indonesia 2
LV - Lettonia 2
TW - Taiwan 2
UZ - Uzbekistan 2
BD - Bangladesh 1
BT - Bhutan 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EC - Ecuador 1
GE - Georgia 1
HK - Hong Kong 1
HR - Croazia 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MM - Myanmar 1
MX - Messico 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 22.785
Salva come PNG Salva come JPEG
Città #
Southend 2.941
Jacksonville 2.514
Woodbridge 1.525
Chandler 1.414
Ann Arbor 934
Houston 823
Dublin 781
Ashburn 722
Wilmington 418
Lawrence 371
Princeton 371
Lancaster 355
Singapore 332
Nanjing 300
Jinan 271
Sindelfingen 262
Shenyang 217
Beijing 181
New York 166
Kent 149
Hebei 145
Changsha 116
Tianjin 105
Boardman 97
Zhengzhou 97
Haikou 91
Nanchang 90
Milan 84
Verona 74
Taizhou 73
Jiaxing 71
Helsinki 69
Ningbo 67
Hangzhou 62
Taiyuan 61
Guangzhou 56
Norwalk 50
Washington 44
Falls Church 42
Lanzhou 40
Seattle 40
Dallas 35
Los Angeles 23
Philadelphia 22
Chicago 21
Fuzhou 21
Auburn Hills 18
Brussels 16
Moscow 14
Rome 14
Dearborn 13
Fairfield 13
Mehlingen 11
Redwood City 11
Seoul 11
Edinburgh 10
Tappahannock 10
San Mateo 9
Qingdao 8
Bucheon-si 7
Clearwater 7
Düsseldorf 7
Radomsko 7
San Diego 7
Toronto 7
Amsterdam 6
Bari 6
Kemerovo 6
Berlin 5
Lappeenranta 5
Madrid 5
Paris 5
Serra 5
Xiangfen 5
Ardabil 4
Catania 4
Chisinau 4
Clifton 4
Enterprise 4
Falkenstein 4
Lisbon 4
Pasian Di Prato 4
Riva 4
San Francisco 4
Sofia 4
Tokyo 4
Torino 4
Venezia 4
Yicheng 4
Augusta 3
Bath 3
Cagliari 3
Caltanissetta 3
Chennai 3
Detroit 3
Dubai 3
Elora 3
Hanover 3
Hongtong 3
Leawood 3
Totale 17.084
Salva come PNG Salva come JPEG
Nome #
Metodo radioimmunologico ed elettrosineresi nello studio dell'antigene Australia (HBAg) e dell'anticorpo (HBAc). Risultati comparativi 269
La regressione della cirrosi epatica: non più un mito. 136
Accuracy of ultrasound in the detection of liver fibrosis in chronic viral hepatitis. 126
Progression to cirrhosis and mortality of chronic hepatiita type B: a cohort study with 25 years follow-up in Italy. 110
TLR4 rs4986790 A>G genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis C. 110
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. 109
A 25 years longitudina study of hepatitis B e antigen positive chornic hepatitis B in italian patients 106
Protease inhibitors-based therapy induces acquired spherocytic-like anemia and ineffective erythropoiesis in chronic HCV patients 104
Suppressor cell function in chronic active hepatitis 103
Malattie autoimmuni del fegato 102
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 102
Endogenously produced TNF-α contributes to the expression of CXCL10/IP-10 in IFN-λ3-activated plasmacytoid dendritic cells 98
HCV gentotype 3 and circulating squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV infected patients. 96
Hepatitis C virus genotype and prognosis of compensated cirrhosis type C 95
A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. 95
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. 93
The homestasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. 93
Membrane oxidative damage causes hemolitic anemia during ribavirin therapy for chronic hepatitis C 92
A long term study of hepatitis G virus coinfection in chronic hepatitis B 91
Role of membrane oxidative damage in the pathogenesis of hemolitic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection 89
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 89
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C 89
Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients. 88
Natural history of hepatitis B e antigen positive chronic hepatitis B in italian patients: a 25 years longitudinal study 88
Consensus interferon (CIFN) in combination with ribavirin (RBV) for naive patients with chronic hepatitis C: a multicenter study 87
Hepcidin suppression relative to iron status in patients with chronic Hepatitits C 87
PEG-interferon and ribavirin in HCV-related cirrhotic patients with profound thrombocytopenia. 85
Genetic polymorphysms of vitamin d pathway predict antiviral treatment outcome in slow responder naive patients with chronic hepatitis C 85
Morbidity and mortality in compensated cirrhosis type C: relationship to interferon alpha therapy 84
Clinical and virological profiles in patients with multiple hepatitis virus infections. 84
A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. 84
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis 83
Relationship between HBcAg in serum and liver and HBV replication in patients with HBsAg-positive chronic liver disease 83
Influence of GB virus-C/Hepatitis G Virus infection on the long term course of chronic hepatitis B 83
Influence of hepatitis delta virus infection on clinical outcome of compensated cirrhosis type B 83
A controlled trial of lymphoblastoid interferon for chronic anti-HBe/HBV-DNA positive hepatitis 83
A survey of clinical toxicity of alfa interferon in chronic viral hepatitis 83
TLR4 rs4986790 A>G . genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis B. 83
Hepatitis B core antigen (HBcAg) in serum of patients with chronic hepatitis B detected by a modified radioimmunoassay 82
Hepatitis C virus genotype and risk of hepatocellular carcinoma in compensated cirrhosis type C 82
Comparison of morbidity and mortality in HBsAg positive cirrhosis with or without hepatitis delta virus superinfection 82
Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study. 82
Heteroimmune and autoimmune reactions to liver cell surface antigens in the pathogenesis of acute and chronic hepatitis 81
Natural history of HBV and HDV infection and liver disease 81
Long term outcome in HBeAg positive cirrhosis treated with interferon alpha: relation between ALT normalization and survival 81
Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. 81
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. 81
Natural history of chronic hepatitis B 81
T and K cell function in acute and chronic hepatitis 81
Interleukin-28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C under real-life conditions 81
Hepatitis C virus genotype and clinical outcome of compensated cirrhosis type C 80
Long-term outcome of chronic hepatitis B in caucasian patients: mortality after 25 years 80
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP) 79
Autoantibodies during alpha-interferon therapy for chronic hepatitis B 79
Serum levels of soluble CD30 in chronic hepatitis type B 79
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. 78
Chronic persistent hepatitis type B can be a progressive disease when associated with sustained virus replication. 78
Delayed clearance of serum HBAg in compensated cirrhosis B:relation to interferon alpha therapy and disease prognosis 78
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage 78
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) Imaging for the Diagnosis of Cirrhosis during Liver Ultrasonography 78
Insulin resistance is not a relevant predictor of sustained virologic response in chronic hepatitis C patients: results from the Italian hepatitis C cohort study (ITAHECS) collaborative group 78
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B 77
[Infection due to hepatitis B virus and host immune response] 77
Hepatitis C and cirrhosis 77
Efficacy of prolonged high dose of interferon (IFN) plus ribavirin in young genotype 1/4 patients with chronic hepatitis C not responding to IFN alone 77
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 77
Antibody dependent cellular cytotoxicity (ADCC) in acute hepatitis B and in chronic active hepatitis 76
Morbidity and mortality in compensated cirrhosis C: a retrospective follow-up study of 384 patients. 76
Reduced serum hepcidin levels in patients with chronic hepatitis C 76
Host genetics regulates liver fibrosis progression in patients with chronic hepatitis C (CHC) 76
Hepatocellularcarcinoma in cirrhosis: incidence and risk factors. 76
Long term course of HGV coinfection in chronic hepatitis type B 75
Cellular immunity to the hepatitis B virion in acute and chronic infection 75
Suppressor cell activity in viral and non-viral chronic active hepatitis 74
Therapy of chronic hepatitis B with lymphoblastoid alfa interferon and levamisole. 74
The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. 74
Effects of interferon plus ribavirin treatment on NF-kB, TGF-b1 and metalloproteinase activity in patients with chronic hepatits C: an in vivo immunohistochemical study 74
Natural history of hepatitis B virus infection and disease 74
Natural course and prognostic factors of hepatitis B. 74
Mutantes del VHB e implicaciones clìnicas. 74
Effectiveness of interferon alfa on the clinical course of caucasian patients with viral compensated cirrhosis 74
Core protein substitution, anti-HBe positive chronic hepatitis and B cell epitopes 74
Hepatitis C genotypes in patients with dual hepatitis B and C virus infection 73
Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients 73
Natural history of chronic hepatitis B virus and Hepatitis delta virus infection and disease 73
Relation between liver disease remission and survival in HBeAg positive cirrhosis treated with interferon alpha 73
Levamisole therapy in chronic type B hepatitis. Results of a double-blind randomized trial. 73
Incidenza e fattori di rischio di epatocarcinoma. 73
A multicenter prospective observational study to evaluate factors influencing efficacy, tolerance and compliance to antiviral treatment with interferon and ribavirin in daily clinical practice 73
HLA-DR expression in liver in human HIV infection 72
Interferon therapy for the anti-HBe positive form of chronic hepatitis B 72
Natural history of hepatitis B and prognostic factors of disease progression 72
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 72
A survey of clinical toxicity of alfa interferon in 11.241 patients with chronic viral hepatitis 72
Antifibrogenic effect of combination interferon plus ribavirin treatment in patients with chronic hepatitis C 72
Efficacy and safety of consensus interferon (CIFN) plus ribavirin (RBV) for naive patients with chronic hepatitis C (CHC): final report of a pilot study 72
Final report of a consensus interferon (CIFN) plus ribavirin (RBV) study for chronic hepatitis C (CHC) 72
Randomized controlled trial of lymphoblastoid interferon alfa in patients with chronic hepatitis B who lacked hepatitis B e antigen. 71
Interferon (IFN) induction followed by prolonged high dose IFN in combination with ribavirin (RBV) for relapsers HCV patients: a randomized controlled multicenter trial 71
Hepatitis D virus (HDV)-related cirrhosis: a case-control study 71
Totale 8.472
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.536
article - articoli 30.699
book - libri 0
conference - conferenze 34.270
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 6.567
Totale 143.072
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.123 0 25 19 391 20 238 148 356 108 382 153 283
2020/20212.964 160 719 180 309 367 260 16 359 152 11 356 75
2021/20222.414 148 544 11 39 295 76 110 174 172 75 263 507
2022/20234.650 434 301 540 931 438 1.052 34 288 451 22 114 45
2023/20242.363 102 186 166 361 398 301 62 114 4 33 456 180
2024/2025732 396 336 0 0 0 0 0 0 0 0 0 0
Totale 22.864